Takeda goes it alone with Ramelteon launch

Share this article:

Japan's top drug maker, Takeda Pharmaceuticals, said yesterday it plans to be the sole marketer of its insomnia drug Ramelteon, marking the first time the company has sold a product in the U.S. on its own.
In the past, the company has worked in conjunction with Abbot Laboratories to market its drugs in the U.S.
Takeda Pharmaceuticals North America, based in Illinois, hopes to release its Ramelteon this fall. DTC and professional advertising will be handled by Abelson-Taylor.
Takeda's North American arm also plans to boost its number of sales reps to 1,800 in the current year, up from around 1,300.
Takeda submitted an NDA for Ramelteon last fall. The company anticipates FDA approval by Fall 2005.


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.